Kura Oncology Inc (NASDAQ: KURA)’s stock price has increased by 1.97 compared to its previous closing price of 7.37. However, the company has seen a -1.76% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-04 that Kura Oncology’s ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax’s revumenib. Kura’s strong cash position supports operations through 2027, bolstered by a lucrative deal with Kyowa Kirin, despite a 50/50 profit share. Market sentiment is low due to second-mover disadvantage and delayed catalysts, but current valuations present a potential buying opportunity.
Is It Worth Investing in Kura Oncology Inc (NASDAQ: KURA) Right Now?
Additionally, the 36-month beta value for KURA is 0.78. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for KURA is 75.15M and currently, short sellers hold a 12.31% ratio of that float. The average trading volume of KURA on March 06, 2025 was 1.67M shares.
KURA’s Market Performance
KURA stock saw a decrease of -1.76% in the past week, with a monthly decline of -15.47% and a quarterly a decrease of -32.90%. The volatility ratio for the week is 5.57%, and the volatility levels for the last 30 days are 6.01% for Kura Oncology Inc (KURA). The simple moving average for the last 20 days is -6.38% for KURA stock, with a simple moving average of -52.65% for the last 200 days.
Analysts’ Opinion of KURA
UBS, on the other hand, stated in their research note that they expect to see KURA reach a price target of $27. The rating they have provided for KURA stocks is “Buy” according to the report published on October 24th, 2024.
Stifel gave a rating of “Hold” to KURA, setting the target price at $19 in the report published on October 14th of the previous year.
KURA Trading at -7.11% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.91% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 5.57%, as shares sank -16.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.77% lower at present.
During the last 5 trading sessions, KURA fell by -1.24%, which changed the moving average for the period of 200-days by -67.12% in comparison to the 20-day moving average, which settled at $8.03. In addition, Kura Oncology Inc saw -13.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from DOYLE THOMAS JAMES, who sale 4,949 shares at the price of $7.87 back on Jan 28 ’25. After this action, DOYLE THOMAS JAMES now owns 88,193 shares of Kura Oncology Inc, valued at $38,958 using the latest closing price.
Leoni Mollie, the Chief Medical Officer of Kura Oncology Inc, sale 4,963 shares at $7.87 during a trade that took place back on Jan 28 ’25, which means that Leoni Mollie is holding 88,253 shares at $39,068 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -3.17 for the present operating margin
- 0.99 for the gross margin
The net margin for Kura Oncology Inc stands at -3.23. The total capital return value is set at -0.25. Equity return is now at value -42.91, with -23.36 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 8.09. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -105.46.
Currently, EBITDA for the company is -169.5 million with net debt to EBITDA at 1.19. When we switch over and look at the enterprise to sales, we see a ratio of 7.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.46.
Conclusion
In conclusion, Kura Oncology Inc (KURA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
